DNVC Portfolio丨Sinovation Back on Nature: Chinese Surgical Robots Empower World-Class Scientific Research
DNVC Portfolio丨Approval for Gynecological Procedures! Surgerii® Robot Becomes the First Single-Port Surgical Robot in China Applicable to Multiple Disciplines
DNVC Portfolio I Xuanzhu Biopharm-Annelrazole sodium enteric-coated tablets (Anjiuwei )successfully included in the national medical insurance directory
DNV Capital Lin Yunfeng was invited to attend Zhaoqing Science and Innovation summit meeting
2019 traditional medicine international development BBS (Europe and Africa)
DNV Capital won the title of 36Kr “the top 10 most powerful business growth venture capital institution in China”.
China Alliance for Rare Disease Holds Inaugural Meeting
Sorrento Therapeutics will Present at Roth Capital Partners 30th Annual Growth Stock Conference
FiRe Convenes Selects TruTag as a 2017 Firestarter Company
Kevin Lin Won the Best Global Cross-border Investors 2016
NEEQ Approved The Investment Project of DNV Capital
Kotler Medical Park - Grand Opening
TruTag Technologies selected Edison Awards Finalist for 2014
Dr. Hank Wuh, Chairman of TruTag., interviewed by Foxnews
Kevin Lin was Awarded the Best Cross-border Investor on ChinaVenture-Hurun Midas List 2016
WuXi PharmaTech Corporate Venture Fund Invests in TruTag
The first TAVI in India
The way forward in valvular disease interventional therapy
DNV Capital sponsored CIC 2014
Trutag was awarded as Health and Safety Product of 2013
Kevin Lin attended Shan Xi Private Capital Forum
Venus – P valve stent was used in China's first PPVI
DNV Capital exits from Vessix Vascular